Novel blood-based microRNA biomarker panel for early diagnosis of pancreatic cancer

查看全文 作　　者：Ganepola AP [1]Ganepola;John R [1]Rutledge;Paritosh [1]Suman;Anusak [2]Yiengpruksawan;David H [1]Chang

机构地区：[1]Center for Cancer Research and Genomic Medicine,The Valley Hospital;[2]Department of Surgery,The Valley Hospital

出　　处：《World Journal of Gastrointestinal Oncology》索引2014年第6卷第1期,共12页

基　　金：Supported by The Valley Hospital Foundation Research Fund and private donations 摘　　要：AIM:To develop a panel of blood-based diagnostic biomarkers consisting of circulating microRNAs for the detection of pancreatic cancer at an early stage.METHODS:Blood-based circulating microRNAs were profiled by high throughput screening using microarray analysis,comparing differential expression between early stage pancreatic cancer patients(n = 8) and healthy controls(n = 11).A panel of candidate microRNAs was generated based on the microarray signature profiling,including unsupervised clustering and statistical analysis of differential expression levels,and findings from the published literature.The selected candidate microRNAs were then confirmed using TaqMan real-time quantitative reverse transcription polymerase chain reaction(RT-qPCR) to further narrow down to a three-microRNA diagnostic panel.The three-microRNA diagnostic panel was validated with independent experimental proce-dures and instrumentation of RT-qPCR at an independent venue with a new cohort of cancer patients(n = 11),healthy controls(n = 11),and a group of high risk controls(n = 11).Receiver operating characteristic curve analysis was performed to assess the diagnostic capability of the three-microRNA panel.RESULTS:In the initial high throughput screening,1220 known human microRNAs were screened for differential expression in pancreatic cancer patients versus controls.A subset of 42 microRNAs was then generated based on this data analysis and current published literature.Eight microRNAs were selected from the list of 42 targets for confirmation study,and three-microRNAs,miR-642b,miR-885-5p,and miR-22,were confirmed to show consistent expression between microarray and RT-qPCR.These three microRNAs were then validated and evaluated as a diagnostic panel with a new cohort of patients and controls and found to yield high sensitivity(91%) and specificity(91%) with an area under the curve of 0.97(P < 0.001).Compared to the CA19-9 marker at 73%,the three-microRNA panel has higher sensitivity although CA19-9 has higher specificity of 100%.CONCLUSION:The identified panel of three microRNA biomarkers can potentially be used as a diagnostic tool for early stage pancreatic cancer. 关键词：MICRORNA Diagnosis Biomarkers PANCREATIC cancer BLOOD plasma CIRCULATING

相关文献

参考文献（16）
引证文献（11）
耦合文献（3）

参考文献(16)

引证文献(11)

耦合文献(3)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Novel blood-based microRNA biomarker panel for early diagnosis of pancreatic cancer

参考文献(16)

引证文献(11)

耦合文献(3)

用户提示